Time for TED thread on MAM.
I hold so this is probably a blatant ramp, but take a look.
The share is now off its low of 11.5p.
Although many got burnt in thr over hype a few years ago, I think the company
Is now well positioned for advancement.
Management have said that more Nucleopure machine sales are in the pipeline.

Have a listen to TEDs CE here, http://www.wallstreetreporter.com/profiles/TepnelLifeSciences.html

Guardian
Finally, it's worth keeping an eye on Tepnel Life Sciences. Market professionals reckon the AIM-listed DNA technology group has been overlooked in the past month and could now enjoy a good run. They note directors recently bought stock and point out that Tepnel's acquisition of Orchid Diagnostics should significantly boost the company's revenue stream and help it reach a much broader customer base. Tepnel closed 0.5p higher at 13p last night.

Sunday Telegraph
Tepnel is close to completing a second acquisition, having just bought the DNA-testing division of Orchid BioSciences, which allows it to enter the US market and increase the customer base for its DNA technology. Buy at 14.25p, the paper says.
regards
dave

ADH
For what it is worth, the two most sceptical punters on this BB, myself a bottom fisher and Bill Z, a disciple of Weinstein charting, are into this share against the background of earlier posts.
And, like you, we are aboard GMC hoping it will reach its pre-cliff fall level of 2000, a fate also suffered by TED.

Impressed with all the directors and institution buys. Can't find what's happening, but they seem to be moving. Any thoughts ?

JAH: Got your tel message. Congrats on buying into TED, up 4% today and should have spanned the spread.
Having been riding on GMC for past month am feeling a need for stress counselling; fortunately this is now available online, and seems to be attracting even more punters than online poker; se ULT.
sd

Now they have come up on someone else's radar. A detailed report about their activities in this weeks 'Trendwatch', and very topical too, with relevances to
Sudan 1 and Birdflu. They recommend Buy.

i thought of buying these a while back,
i also remember director buys at about 10p
so might worth a whirl,good luck!

TED on the move at last? Looks like a bounce off the bottom of the 4.5-7p trading range since Aug`04.Recent average volume is als up.

Any news?

Looks as though last week's wobble on the NASDAQ depressed TED for a second bottom, but now again showing signs of upward movement. I'm beginning to feel comfortable with these for the long haul, having followed the directors aboard after their hefty share buys at end of November.
sd.

Larger than normal trades today 02/06/05 (apparently buys)and yesterday(apparently sells !). Anybody know if there is something happening?

BZ: After a wait of about 6 months, TED is now showing signs of life. We learned yesterday that Bio-Rad Laboratories of California had picked up 8M shares but I cannot find anything to justify the 35% sp jump today. There was though, a story in the weekend press of bird flu infecting geese which means that it could be on its way here.
sd.

BZ: Have decided that this is a good time to take profits on TED as I fear that the drift on low volumes will resume when the excitement dies down, so have sold all. A 50% gain isn't bad for a recovery stock.
sd.

Morning all,
This is a very quiet thread!, i bought some of these yesterday as the interims are due this month, and with the co. declining an offer above the sp on the 5th Sept. i think they are very good for a medium term punt.
the last 2 RNS`s.
Dexter

Offer Talks Terminated

RNS Number:8060Q
Tepnel Life Sciences PLC
05 September 2005




TEPNEL LIFE SCIENCES PLC

STATEMENT RE POSSIBLE OFFER FOR TEPNEL


Further to the announcement made on 14 July 2005, Tepnel Life Sciences PLC (AIM:
TED) ('Tepnel' or 'the Company') the UK-based international Research Products &
Services and Molecular Diagnostics group, announces today that talks with
potential offerors for the Company have been terminated by the Tepnel Board. The
Company continues to talk with various parties on a number of commercial
collaborations including distributorships and joint venture opportunities.

Whilst a proposed valuation of the Company received from a third party was above
the current share price, the Board believes that such a valuation underestimated
the present and future potential value of Tepnel. Consequently the Board of the
Company is not in a position to recommend to shareholders any of the proposals
made to the Company. The Board believes it has an excellent future as an
independent company and will continue to explore means of building and enhancing
returns to its shareholders.

The Board looks forward to updating shareholders of the further significant
progress in its financial performance when the interim results for the six
months ended 30 June 2005 are released in September. In a recent trading
statement issued in July, Tepnel announced that Group sales this year were
approximately 35% ahead of the same period last year at #6.85m (unaudited)
(2004: #5.07m). Sales for second quarter of the year were approximately #3.66m
(unaudited). The Company expects to maintain significant sales growth for the
remainder of the year.

Tepnel's management team is focused on delivering value to shareholders. The
Board of Tepnel firmly believes that the current strategy of the Group will
result in continued delivery of growth and excellent returns to shareholders.



About Tepnel

Tepnel is a UK based international biotechnology company. The Company has
laboratories, manufacturing and operations in the USA, UK and France with 175
employees. Tepnel provides test kits, reagents and services to two highly
synergistic markets, these being Molecular Diagnostics and Biomedical Research.
The company's strategy has been to identify high growth niche opportunities
within these multi-billion pound markets. Tepnel focuses on these niche
opportunities with internally developed products, patents, expertise and
know-how as well as strategic acquisitions, to develop a leadership position
within these defined market segments.

Enquiries:

Ben Matzilevich, Chief Executive Officer, Tepnel Life Sciences plc 0161 946 2200
Gron Ffoulkes-Davies, Finance Director, Tepnel Life Sciences plc 0161 946 2200
Mark Percy, Seymour Pierce Limited 0207 107 8000
Richard Anderson, De Facto Communications Ltd 0207 940 1000




This information is provided by RNS
The company news service from the London Stock Exchange

END
+++++++++++++++++++++++++++++++++++++++

Licence agreement

RNS Number:8062Q
Tepnel Life Sciences PLC
05 September 2005





Tepnel Life Sciences PLC ('Tepnel' or 'the Company')

Tepnel licences rights to routine chromosome detection tests


Manchester, U.K. Tepnel (AIM: TED) announces that it has licenced the global
rights to develop, manufacture and market a DNA-based diagnostic assay for the
rapid prenatal detection of common fetal chromosome abnormalities, including
Down Syndrome. The simple one tube test uses QF-PCR (Quantitative Fluorescence
Polymerase Chain Reaction) technology that provides a rapid and cost effective
alternative to conventional chromosome analysis with results being routinely
reported in less than 2 days.

The rights have been licenced from Guy's and St Thomas' NHS Foundation Trust in
the UK. Guy's Hospital is one of the founders of the application of QF-PCR for
routine diagnostic procedures. The assay developed by Guy's has been implemented
by other laboratories in the UK and overseas; rapid prenatal testing is now
recognised as a basic standard of prenatal health care.

Tepnel is a leader in the development and manufacture of in vitro diagnostic
products for the predisposition and diagnosis of human genetic disease. The
ELUCIGENE brand of CE marked products has for the past 10 years provided
efficient and simple methods for genetic testing and screening mutations
responsible for human inherited disease and are routinely used in many
laboratories around the world. Tepnel Diagnostics will develop and manufacture
the QF-PCR assays under licence from Guy's & St. Thomas' NHS Foundation Trust as
a fully validated and CE marked in vitro diagnostic product enabling diagnostic
laboratories to easily implement this rapid and cost effective technology into
routine genetic testing.

Pregnant women at elevated risk of fetal chromosome abnormalities (as determined
by age, serum markers or ultrasound) are routinely offered prenatal diagnosis.
Approximately 40,000 amniocentesis or chorionic villus samples are taken in the
UK each year for chromosome abnormality testing. Approximately 8% of these
samples do exhibit an abnormality, the majority of which are the chromosome
aneuploidies, trisomy 13 (Patau syndrome), trisomy 18 (Edwards syndrome) and
trisomy 21 (Down Syndrome). The Tepnel test for these common chromosome
aneuploidies will be available later this year under the name Elucigene QST*R.


Useful links:
www.tepnel.co.uk

www.elucigene.com

For further information

Tepnel Life Sciences plc
Ben Matzilevich, CEO
Gron Ffoulkes-Davies, Finance Director

0161 946 2200


Seymour Pierce

Mark Percy, Corporate Finance
0207 107 8000

De Facto Communications

Richard Anderson
020 7940 1000

Notes to Editors

About Tepnel Life Sciences plc
Tepnel is a UK based international biotechnology company. The Company has
laboratories, manufacturing and operations in the USA, UK and France with 175
employees. Tepnel provides test kits, reagents and services to two highly
synergistic markets, these being Molecular Diagnostics and Biomedical Research.
The company's strategy has been to identify high growth niche opportunities
within these multi-billion pound markets. Tepnel focuses on these niche
opportunities with internally developed products, patents, expertise and
know-how as well as strategic acquisitions, to develop a leadership position
within these defined market segments.




This information is provided by RNS
The company news service from the London Stock Exchange

END
MSCZGGGLRZMGKZM

keep watching!, results soon (sept) and good, keeps ticking up day on day

And a lot of activity this morning - more bid activity perhaps ?

upwards and onwards!!!

someone has some real faith!


Tepnel Life Sciences PLC
13 September 2005

13 September 2005

Tepnel Life Sciences plc ('the Company')

Holding in Company

The Company received notification on 13 September 2005 that, following recent
purchases, Mr. J M Harvey has a notifiable interest in 9,441,909 ordinary shares
of 1p each in the Company representing approximately 4.43 per cent of the issued
share capital.

About Tepnel

Tepnel Life Sciences (TLS) is a UK based international biotechnology company.
The Company has laboratories, manufacturing and operations in the USA, UK and
France with 175 employees. TLS provides test kits, reagents and services to two
highly synergistic markets, these being Molecular Diagnostics and Biomedical
Research. The company's strategy has been to identify high growth niche
opportunities within these multi-billion pound markets. TLS focuses on these
niche opportunities with internally developed products, patents, expertise and
know-how as well as strategic acquisitions, to develop a leadership position
within these defined market segments

Morning all,
Well, the results are in and they are very very positive, this is definitely a medium term punt, but very much under-valued at the moment IMO.
Dexter.

+++++++++++++++++++++++
Tepnel Life Sciences PLC
15 September 2005







Tepnel Life Sciences plc ('Tepnel' or 'the Company')

Interim results for the 6 months ended 30 June 2005



Manchester, UK, 15 September 2005: Tepnel Life Sciences plc (AIM: TED), the
UK-based international Research Products & Services and Molecular Diagnostics
group, is pleased to announce its interim results for the six month period ended
30 June 2005.

Summary

Group sales totalled 6.89m, an increase of 36% over the same period
last year (6 months to 30 June 2004: 5.07m)

Pre-tax losses for the Group decreased 61% to 0.36m (6 months to 30
June 2004: 0.92m)

End of period cash totalled 1.81m. With cash balances at 31 March
2005 of 1.80m (unaudited), the second quarter of the year was marginally cash
positive

Recently acquired Diaclone signs a comprehensive research
collaboration with Boehringer Ingelheim to generate murine monoclonal antibodies
that recognise human immune regulatory cells

Introduction of ELUCIGENE CF-HT kits for rapid, high-throughput cystic
fibrosis testing, marks significant extension of the highly profitable ELUCIGENE
product group

Ben Matzilevich, Chief Executive Officer commented: 'We are pleased and
gratified with our first half performance. These results demonstrate that our
decision, taken in the Spring of 2005, to focus our business strategy on the
highly profitable areas of Research Products & Services and Molecular
Diagnostics has quickly shown itself to be a successful one. The recent
acquisition of Diaclone in December 2004 has also significantly increased our
capabilities for antibody and assay development. The integration of Diaclone
allows us to offer an extended menu of analytical services to our pharmaceutical
customers, a broader catalogue of research reagents and will enable us to
develop new tests for Molecular Diagnostics.'






CHAIRMAN'S STATEMENT

Interim Results for the 6 months ended 30 June 2005



Financial Results

In the six months ended 30 June 2005, turnover for the Group increased 36% to
6.89m (6 months to 30 June 2004: 5.07m) including revenues from the newly
acquired Diaclone business.



Pre-tax losses for the Group during the period decreased 61% to 0.36m (6 months
to 30 June 2004: 0.92m).



The loss per share during the period decreased to 0.1p (6 months to June 30
2004: 0.6p).



Cash and cash equivalents at the end of the period were 1.81m. With cash
balances at 31 March 2005 at 1.80m (unaudited), the second quarter of the year
was marginally cash positive.



Overview

The first half of 2005 has been an outstanding success for Tepnel, both
financially and in terms of product development. Ongoing operations and the
completion of our acquisition of Diaclone have led us to our strongest financial
performance since the arrival of the new executive management team in 2001 with
half-year sales totalling 6.89m. This represents an impressive 36% increase in
Group sales over the same period last year.

Overall pre-tax losses for the six month period were reduced 61% to 0.36m (6
months to 30 June 2004: 0.92m). The second quarter of 2005 also marked the
Group's further progress towards profitability, as cash balances at the end of
the period exhibited a marginal increase over the end of the previous quarter.
This follows a strategic decision made by the Board in March of this year to
focus the business on the highly profitable areas of Research Products &
Services and Molecular Diagnostics. By concentrating our development efforts on
these two segments, while withdrawing from the smaller DNA purification
instrument business, the Group made considerable progress towards establishing
production synergies that will further support the continuing drive towards
profitability.

The Group's strong commercial viability has also made a significant impact
within our industry. As we announced in July, the Board received a number of
approaches ranging from offers for the Group, to Joint Venture and distribution
agreements. Whilst a proposed valuation of the Group received from a third
party was above the current share price, the Board announced on 5 September that
they believed that such a valuation underestimated the present and future
potential value of Tepnel and consequently were not in a position to recommend
to shareholders any of the proposals made to the Group. Moving forward, our
greater commercial focus, recent acquisitions and unique product lines are
expected to further enhance our attractiveness to the international investment
community and drive our progress as one of today's most dynamic life sciences
companies.

Molecular Diagnostics

Period sales for the Molecular Diagnostics Division were ahead approximately 35%
over the previous year. Key products contributing to growth in this area
include the Tepnel Lifecodes (TLC) LIFEMATCH(R) antibody detection system for
use with LuminexTM multiplex analysis technology. This line has continued to
capture market share in the HLA/DNA typing marketplace due to its high
sensitivity, short assay times and low reagent use.

Future growth in this area is expected to be strengthened by 510(k) clearance
received in August this year from the U.S. Food and Drug Administration (FDA)
for TLC's DNA typing kits for HLA-A, HLA-B, HLA-C, HLA-DQB, and HLA-DRB, which
allows the products to be marketed for in-vitro Diagnostic use. The use of
these kits with the Luminex 100 instrument system provides clinicians with a
highly automated testing system that minimises the occurrence of sample loss or
contamination. The worldwide market for transplant diagnostics is estimated at
$150m, with the U.S. market representing approximately 40% of this total.
Additionally, the emerging field of post-transplant monitoring is expected to
add a new application for these kits in a market that is growing at an estimated
rate of nearly 20% per annum.

Tepnel Diagnostics (TD) also exhibited an increased market presence as sales of
genetic pre-disposition kits and services increased by 30%. The ELUCIGENETM
range of products for simple and rapid mutation detection has been a crucial
driver of this growth and in March of this year, this group was extended with
the introduction of ELUCIGENE CF-HT for high-throughput cystic fibrosis testing.
Featuring an advanced fluorescent format of the already well-validated ARMSTM
technology, these kits are capable of detecting 30 of the most common causative
mutations of cystic fibrosis, providing clinical testing laboratories with
cost-effective and reliable results.

The Group announced recently that it has licenced the global rights to develop,
manufacture and market a DNA-based diagnostic assay for the rapid prenatal
detection of common foetal chromosome abnormalities, including Down Syndrome.
This product has generated considerable market interest in the UK medical
diagnostics community ahead of its anticipated launch in late 2005.

Research Products & Services

Overall sales from Tepnel's Research Products & Services Division increased
approximately 38% from the same period last year. This division comprises the
Group's activities in DNA purification (TLS), outsourcing services for the
pharmaceutical and healthcare industries (TSS), food safety (TBS) and the
recently acquired Diaclone business engaged in monoclonal antibody products and
development services.

Tepnel Life Sciences (TLS) revenues from DNA purification contracted
approximately 19% during the first half of the year, due to delays in receipt of
customer samples. Recent contract awards and scheduling of sample receipts in
the second half of the year indicate a resumption of growth from this activity
for the year as a whole.

Tepnel BioSystems (TBS) continued to grow its revenues from allergen and toxin
testing and from animal and fish speciation in foods. Distribution of products
into the U.S. through the TLC facility in Stamford has begun to gain some
momentum in that market, resulting in improved operating margins compared to the
prior year period. TBS traded profitably and generated cash during the first
half of the year.

Revenues from Tepnel Scientific Services (TSS) grew 23% during the first half of
the year with the principal growth being derived from analytical chemistry and
bio-analysis services. Revenue growth is expected to remain at a similar rate
to the year-end. TSS traded profitably and generated cash during the first half
of the year and is expecting a successful outcome to the year. TSS is now well
advanced in its plans to relocate its Edinburgh and Glasgow facilities to new
purpose built laboratories in Livingston, Scotland. Solicitors have been
instructed to finalise the site acquisition and construction agreements. At
this stage, construction is expected to commence in October 2005 with an
anticipated completion date of end June 2006.

The integration of Diaclone has also been highly rewarding to the Division,
beginning with the signing of a research collaboration agreement with Boehringer
Ingelheim in January. Diaclone expands Tepnel's capabilities geographically and
at the level of product services. Located in Besancon, France, Diaclone has a
presence in over 30 countries and is a leader in the field of antibody and assay
development. In the first six months of 2005, this has already enabled the
Company to offer a broader menu of analytical services to our pharmaceutical
customers, expanded our research reagents catalogue and created cross-selling
opportunities for other business segments within the division.

Prospects

The Group has had an excellent first six months in 2005. Streamlining our
business around profitable, core operations has had an excellent positive
reflection in Group sales, while opening the possibility for operational
synergies. Through the remainder of 2005, the Group will look to identify other
key areas in which our business could benefit from these synergies and to
further capitalise on recent acquisitions.

Looking ahead, Tepnel remains focused on delivering high-quality products and
services to its customers and on competing effectively in the global biotech
market. By carefully examining every viable opportunity for growth in these
areas, we are confident that we will maintain our ultimate objective of
increasing the value of our Company to our shareholders, while creating a
challenging and rewarding workplace for our employees.

Alec Craig
Non-Executive Chairman
15 September 2005



For Further Information:



Tepnel Life Sciences plc
Ben Matzilevich, CEO
Gron Ffoulkes-Davies, Group Finance Director
0161 946 2200

Seymour Pierce
Mark Percy, Corporate Finance
020 7107 8000

De Facto Communications
Richard Anderson

forgot to post the figures!!

++++++++++++++++++++++++
Consolidated Profit & Loss Account for the 6 months ended 30 June 2005

6 months ended 30 Audited 6 months
June 2005(1) Year ended 31 ended 30 June 2004(1)
December 2004
'000 '000 '000
Turnover 6,893 10,193 5,068
Cost of sales (2,804) (5,467) (2,974)
Gross profit 4,089 4,726 2,094

Research and development (953) (1,553) (636)
Sales and marketing (1,421) (2,185) (994)
Administrative expenses (2,106) (2,722) (1,395)
Administrative expenses - - (547) -
exceptional(2)
Total administrative expenses (2,106) (3,269) (1,395)
Total expenses (4,480) (7,007) (3,025)
Operating loss (391) (2,281) (931)
Interest receivable 35 43 26
Interest payable (5) (23) (17)
Loss on ordinary activities before (361) (2,261) (922)
taxation
Taxation 69 19 60
Loss on ordinary activities after (292) (2,242) (862)
taxation
Basic and diluted loss per share 0.1p 1.5p 0.6p



Statement of Total Recognised Gains and Losses for the 6 months ended 30 June
2005


6 months Audited 6 months ended 30
ended 30 June Year ended 31 December June 2004(1)
2005(3) 2004
'000 '000 '000
Loss for the period (292) (2,242) (862)
Currency translation differences on (21) (36) 13
foreign currency net investments
Total gains and losses recognised (313) (2,278) (849)



Consolidated Balance Sheet as at 30 June 2005

30 June 2005(4) Audited 30 June 2004(1)
31 December 2004
'000 '000 '000
Fixed assets
Intangible fixed assets 1,762 1,882 502
Tangible fixed assets 1,675 1,851 1,933
3,437 3,733 2,435
Current assets
Stocks 2,412 2,279 2,245
Debtors: due within one year 3,615 2,932 3,357
Cash at bank and in hand 1,807 2,542 1,474
7,834 7,753 7,076
Creditors: amounts falling due (4,025) (3,927) (4,003)
within one year
Net current assets 3,809 3,826 3,073
Total assets less current 7,246 7,559 5,508
liabilities
Creditors: amounts falling due after - - (64)
more than one year
Net assets 7,246 7,559 5,444

Capital and reserves(5)
Called up share capital 2,129 2,129 1,385
Share premium account 33,588 33,588 30,788
Profit and loss account (28,471) (28,158) (26,729)
Equity shareholders' funds 7,246 7,559 5,444



Consolidated Cash Flow Statement for the 6 months ended 30 June 2005


6 months Audited 6 months
ended 30 June 2005 Year ended 31 December ended 30 June 2004(1)
(6) 2004
'000 '000 '000
Consolidated cash flow statement
Net cash outflow from operating (574) (1,057) (1,389)
activities
Returns on investments and 30 20 9
servicing of finance
Acquisitions - (3,838) (1,967)
Corporation tax - 180 (98)
Capital expenditure (125) (317) 342
Net cash outflow before financing (669) (5,012) (3,103)
Financing (66) 3,310 333
Decrease in cash (735) (1,702) (2,770)


Reconciliation of operating loss to net
cash outflow from operating activities:
Operating loss (391) (2,281) (931)
Depreciation 300 596 324
Amortisation 109 56 -
(Increase)/decrease in stocks (133) 572 (1,250)
(Increase)/decrease in debtors (619) 228 (1,876)
Increase/(decrease) in creditors 160 (227) 2,344
Other non-cash movements - (1) -
Net cash outflow from operating
activities (574) (1,057) (1,389)




Reconciliation of net cash flow to
movement in net funds
Decrease in cash (735) (1,702) (2,770)
Cash outflow from decrease in lease 66 132 65
financing
Issued debt - (550) -
Change in net funds resulting from cash (669) (2,120) (2,705)
flows
Conversion of debt to equity - 550 -
Net funds at beginning of period 2,398 3,968 3,968
Net funds at end of period 1,729 2,398 1,263




Notes

1 The Interim Report for the six months ended 30 June 2005 is unaudited and was approved by
the directors. The financial information set out above does not constitute statutory
accounts within the meaning of section 240 of the Companies Act 1985. The information for
the comparative figures has been extracted from the previously published Interim and Annual
Reports. The Annual Report from which the information for the year ended 31 December 2004
has been delivered to the Registrar of Companies and contained an unqualified audit opinion.

2 The directors do not recommend the payment of an interim dividend.

3 The accounting policies used are consistent with those applied in the latest published
consolidated accounts.

4 Segmental analysis
6 months ended 30 June 2005(7)
Turnover by geographical Research Products Molecular Total
destination and Services Diagnostics
'000 '000 '000
UK 1,624 300 1,924
Rest of Europe 1,111 875 1,986
US 72 1,877 1,949
Asia 6 342 348
Rest of World 63 623 686
2,876 4,017 6,893





Audited
Year ended 31 December 2004

Turnover by geographical Research Products Molecular Total
destination and Services Diagnostics
'000 '000 '000
UK 3,251 326 3,577
Rest of Europe 614 1,786 2,400
US 79 3,271 3,350
Asia 10 462 472
Rest of World 114 280 394
4,068 6,125 10,193


6 months ended 30 June 2004(1)
Turnover by geographical Research Products Molecular Total
destination and Services Diagnostics
'000 '000 '000
UK 1,640 310 1,950
Rest of Europe 340 592 932
US 41 1,771 1,812
Asia 4 1 5
Rest of World 61 308 369
2,086 2,982 5,068





5 The basic and diluted loss per share has been calculated on the following basis:
6 months Audited 6 months ended 30
ended 30 June Year ended 31 December June 2004(1)
2005(8) 2004
Loss for the period (292) (2,242) (862)
('000)
Weighted average no. of 212,927,315 148,403,632 134,244,887
shares

In the current period the average number of shares is the same on a diluted basis.

6 Copies of this statement are being sent to all shareholders and will be available to the public at the
Company's Registered office at Heron House, Oaks Business Park, Crewe Road, Wythenshawe, Manchester M23
9HZ.



--------------------------


(1) Neither audited or reviewed.


(2) Exceptional items comprise costs relating to restructuring (506k) and redundancy costs (41).


(3) Neither audited or reviewed.


(4) Neither audited or reviewed.


(5) All items under capital and reserves are equity.


(6) Neither audited or reviewed.


(7) Neither audited or reviewed


(8) Neither audited or reviewed.


This information is provided by RNS
The company news service from the London Stock Exchange

Morning all,
This bit of press came from the Manchester Evening News( local, but still press!).

+++++++++++++++++++++++++++++

Tepnel heading towards profits
Chris Barry
TEPNEL Life Sciences, the biotech firm specialising in molecular diagnosis, heralded an "excellent" first half performance as sales soared 36 per cent and losses fell by 60 per cent.

The Manchester company, which said earlier this month that it had turned down a takeover approach from an un-named suitor, said it was in good shape to move into profitability.

Sales in the six months to June 30 rose 36 per cent from 5.07m to 6.89m. Losses fell 61 per cent from 920,000 to 360,000.




Tepnel's US-based chief executive Ben Matzilevich said he was "pleased and gratified" with the improved performance.

Alec Craig, the Manchester corporate lawyer who chairs Tepnel, described the performance as "an outstanding success", and said he was confident for the future.

He outlined why the bid approach had been shunned: "The board believed the valuations underestimated the present and future value of Tepnel and consequently were not in a position to recommend to shareholders any of the proposals made."

Tepnel's shares were unchanged at 8.25p, valuing the company at 17.5m.

Nice to see this one doing better, still down on what I paid (just) in 04 but got a nice bit in shares mag today.
2517

Small buying by directors yesterday.
2517